BioSpace News Archive

Rhinomed Ltd invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Seqirus, a global leader in influenza prevention, is presenting key research at the Canadian Immunization Conference 2020 (CIC) contributing to Canadian public health pro

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced the last patient has completed her final visit in Mycovia’s last Phase 3 clinical trial of oteseconazole (VT-1161) in patients with recurrent vulvovaginal candidiasis (RVVC).

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414, which covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib resistant cancer and cancer with a T790M EGFR mutation.

Muno-Vax Biotechnologies, together with manufacturer Natstim, Ltd of Sofia, Bulgaria, has developed products that promote immune health - including supporting respiratory health, men’s prostate health, and oral health.

Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired).

Medicure Inc. (" Medicure " or the " Company ") (TSXV: MPH) (OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that it has retained the services of Renmark Financial Communications Inc. (" Renmark ") to condu

Financing led by Blumberg Capital supports Segmed’s mission to aggregate medical data for research in support of improving healthcare around the world

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 50,000 shares of common stock to one new employee.